TY - JOUR
T1 - Mediation of insulin hyperphagia by specific central opiate receptor antagonists
AU - Beczkowska, Iwona W.
AU - Bodnar, Richard J.
N1 - Funding Information:
This research was supported by NIH DA04194-01A2 (R.J.B.). We thank Drs. G.W. Pasternak and W.D. Bowen for providing naloxonazine and DALCE respectively.
PY - 1991/5/3
Y1 - 1991/5/3
N2 - The hyperphagic properties of insulin (10 U/kg, s.c.) were transiently (2 h) and dose-dependently inhibited (30%) by central pretreatment with naltrexone (20-50 μg, i.c.v.). The irreversible μ opioid antagonist, β-funaltrexamine (B-FNA, 20 μg, i.c.v.) significantly inhibited insulin hyperphagia by 28-54% over the 6-h time course. In contrast, insulin hyperphagia was only transiently (2 h) inhibited (27-30%) by either the irreversible μ1 antagonist, naloxonazine (50 μg, i.c.v.) or the selective κ antagonist, nor-binaltorphamine (NorBNI, 20 μg, i.c.v.). The δ-antagonistic actions of [d-Ala2, Leu5, Cys6]-enkephalin (DALCE, 40 μg, i.c.v.) failed to affect insulin hyperphagia. These data suggest that the μ2 opioid receptor subtype modulates insulin hyperphagia.
AB - The hyperphagic properties of insulin (10 U/kg, s.c.) were transiently (2 h) and dose-dependently inhibited (30%) by central pretreatment with naltrexone (20-50 μg, i.c.v.). The irreversible μ opioid antagonist, β-funaltrexamine (B-FNA, 20 μg, i.c.v.) significantly inhibited insulin hyperphagia by 28-54% over the 6-h time course. In contrast, insulin hyperphagia was only transiently (2 h) inhibited (27-30%) by either the irreversible μ1 antagonist, naloxonazine (50 μg, i.c.v.) or the selective κ antagonist, nor-binaltorphamine (NorBNI, 20 μg, i.c.v.). The δ-antagonistic actions of [d-Ala2, Leu5, Cys6]-enkephalin (DALCE, 40 μg, i.c.v.) failed to affect insulin hyperphagia. These data suggest that the μ2 opioid receptor subtype modulates insulin hyperphagia.
KW - Insulin hyperphagia
KW - Naloxonazine
KW - Naltrexone
KW - Nor-binaltorphamine
KW - Opioid receptor subtype
KW - [d-Ala, Leu, Cys]-Enkephalin
KW - β-Funaltrexamine
UR - http://www.scopus.com/inward/record.url?scp=0025843633&partnerID=8YFLogxK
U2 - 10.1016/0006-8993(91)90977-4
DO - 10.1016/0006-8993(91)90977-4
M3 - Article
C2 - 1653080
AN - SCOPUS:0025843633
SN - 0006-8993
VL - 547
SP - 315
EP - 318
JO - Brain Research
JF - Brain Research
IS - 2
ER -